JP7026440B2 - ハイブリッドｔＲＮＡ／プレｍｉＲＮＡ分子および使用方法 - Google Patents

ハイブリッドｔＲＮＡ／プレｍｉＲＮＡ分子および使用方法 Download PDF

Info

Publication number
JP7026440B2
JP7026440B2 JP2016569679A JP2016569679A JP7026440B2 JP 7026440 B2 JP7026440 B2 JP 7026440B2 JP 2016569679 A JP2016569679 A JP 2016569679A JP 2016569679 A JP2016569679 A JP 2016569679A JP 7026440 B2 JP7026440 B2 JP 7026440B2
Authority
JP
Japan
Prior art keywords
trna
mir
rna
cells
mirna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016569679A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017524341A (ja
JP2017524341A5 (https=
Inventor
エイミング ユ
ウェイペン ワン
チウシャ チェン
メイメイ リ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2017524341A publication Critical patent/JP2017524341A/ja
Publication of JP2017524341A5 publication Critical patent/JP2017524341A5/ja
Application granted granted Critical
Publication of JP7026440B2 publication Critical patent/JP7026440B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2016569679A 2014-05-28 2015-05-21 ハイブリッドｔＲＮＡ／プレｍｉＲＮＡ分子および使用方法 Active JP7026440B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462003806P 2014-05-28 2014-05-28
US62/003,806 2014-05-28
PCT/US2015/031861 WO2015183667A1 (en) 2014-05-28 2015-05-21 HYBRID tRNA/pre-miRNA MOLECULES AND METHODS OF USE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020121186A Division JP2021003105A (ja) 2014-05-28 2020-07-15 ハイブリッドｔＲＮＡ／プレｍｉＲＮＡ分子および使用方法

Publications (3)

Publication Number Publication Date
JP2017524341A JP2017524341A (ja) 2017-08-31
JP2017524341A5 JP2017524341A5 (https=) 2018-06-28
JP7026440B2 true JP7026440B2 (ja) 2022-02-28

Family

ID=54699588

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016569679A Active JP7026440B2 (ja) 2014-05-28 2015-05-21 ハイブリッドｔＲＮＡ／プレｍｉＲＮＡ分子および使用方法
JP2020121186A Pending JP2021003105A (ja) 2014-05-28 2020-07-15 ハイブリッドｔＲＮＡ／プレｍｉＲＮＡ分子および使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020121186A Pending JP2021003105A (ja) 2014-05-28 2020-07-15 ハイブリッドｔＲＮＡ／プレｍｉＲＮＡ分子および使用方法

Country Status (4)

Country Link
US (1) US10619156B2 (https=)
EP (1) EP3160980B1 (https=)
JP (2) JP7026440B2 (https=)
WO (1) WO2015183667A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201504038XA (en) 2012-11-27 2015-06-29 Childrens Medical Center Targeting bcl11a distal regulatory elements for fetal hemoglobin reinduction
MX375592B (es) 2014-04-25 2025-03-06 The Children´S Medical Center Corp Composiciones y su uso para tratar hemoglobinopatias.
EP3160980B1 (en) 2014-05-28 2020-05-20 The Regents of the University of California HYBRID tRNA/pre-miRNA MOLECULES AND METHODS OF USE
CA3193811A1 (en) 2014-11-14 2016-05-19 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
CN119876138A (zh) 2014-11-14 2025-04-25 沃雅戈治疗公司 调节性多核苷酸
WO2016153880A2 (en) * 2015-03-23 2016-09-29 The Regents Of The University Of California Methods for detection of rnase activity
ES2835861T5 (en) 2015-05-08 2025-02-18 Childrens Medical Ct Corp Targeting bcl11a enhancer functional regions for fetal hemoglobin reinduction
CA3024448C (en) 2016-05-18 2025-09-09 Voyager Therapeutics, Inc. MODULATING POLYNUCLEOTIDES
CA3024449A1 (en) 2016-05-18 2017-11-23 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
CN106032533B (zh) * 2016-08-04 2018-11-20 北京信生元生物医学科技有限公司 一种抑制肿瘤生长和转移的短链核酸及其应用
CN108295259A (zh) * 2017-01-13 2018-07-20 昆山彭济凯丰生物科技有限公司 通过miR-6792-3p进行抗癌的方法和药物及其应用
CN108310382A (zh) * 2017-01-16 2018-07-24 昆山彭济凯丰生物科技有限公司 通过miR-6846-3p进行抗癌的方法和药物及其应用
CN106987634B (zh) * 2017-04-18 2020-12-22 优联瑞康(上海)基因科技有限公司 血浆外泌体源性miRNAs在制备早期诊断原发性肝癌的试剂盒中的应用
EP3618839A4 (en) 2017-05-05 2021-06-09 Voyager Therapeutics, Inc. COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
JP2020518259A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ハンチントン病治療組成物および方法
US11788087B2 (en) 2017-05-25 2023-10-17 The Children's Medical Center Corporation BCL11A guide delivery
WO2019079242A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
TW202413649A (zh) 2017-10-16 2024-04-01 美商航海家醫療公司 肌萎縮性脊髓側索硬化症(als)之治療
TWI688655B (zh) * 2017-11-06 2020-03-21 高雄醫學大學 甘胺酸ｎ-甲基轉移酶剔除小鼠應用高通量定序法建立新穎微小核醣核酸癌症與肝臟疾病標誌物與套組
AU2019237514A1 (en) 2018-03-23 2020-10-08 University Of Massachusetts Gene therapeutics for treating bone disorders
US11702657B2 (en) 2018-04-20 2023-07-18 The Regents Of The University Of California TRNA/pre-miRNA compositions and methods for treating hepatocellular carcinoma
US12522811B2 (en) 2018-05-01 2026-01-13 The Children's Medical Center Corporation Enhanced BCL11A RNP / CRISPR delivery and editing using a 3XNLS-CAS9
US12350284B2 (en) 2018-05-02 2025-07-08 The Children's Medical Center Corporation BCL11A microRNAs for treating hemoglobinopathies
US11946049B2 (en) 2018-05-22 2024-04-02 The Regents Of The University Of California tRNA/pre-miRNA compositions and use in treating cancer
CN108753780B (zh) * 2018-06-11 2022-03-29 西安荣清畅生物科技有限公司 一种重组小rna的生产方法及应用
CN108707625B (zh) * 2018-07-03 2021-09-21 云笛生物科技有限公司 mir-124和HER2-shRNA双基因表达盒病毒载体、构建方法、病毒、应用
CN109022442B (zh) * 2018-08-31 2020-12-18 武汉大学中南医院 一种可有效抑制骨肉瘤生长的生物重组型miR124-3p
WO2021062096A1 (en) 2019-09-26 2021-04-01 Massachusetts Institute Of Technology Microrna-based logic gates and uses thereof
GB201919021D0 (en) 2019-12-20 2020-02-05 Reneuron Ltd Nucleic acid constructs for delivering polynucleotides into exosomes
TWI845834B (zh) 2020-04-23 2024-06-21 輔仁大學學校財團法人輔仁大學 癌症化療藥物促敏方法、其促敏劑組合物及其用途
CN113604471A (zh) * 2021-09-10 2021-11-05 西北工业大学 一种重组miR-218及其生产方法和在毛发再生中的应用
CN114854744A (zh) * 2022-04-17 2022-08-05 吉布森生物科技(陕西)有限公司 一种重组anti-miR-129-5p及其制备方法和在抗皮肤衰老中的应用
CN115181746B (zh) * 2022-06-08 2024-11-19 浙江树人学院 mgr-mir-9在调控拟禾本科根结线虫侵染水稻能力中的应用
WO2024020376A1 (en) * 2022-07-22 2024-01-25 University Of Massachusetts Aav-mediated delivery of osteoblast/osteoclast-regulating mirnas for osteoporosis therapy
WO2025155837A1 (en) * 2024-01-19 2025-07-24 Massachusetts Institute Of Technology Modular microrna expression from self-replicating rna (replicons)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090298920A1 (en) 2006-06-14 2009-12-03 Universite Rene Descartes - Paris V Chimeric transfer rna and use thereof for the production of rna by a cell
JP2010527616A (ja) 2007-05-23 2010-08-19 ダーマコン， インコーポレイテッド マイクロ−ｒｎａスキャホールドおよび非天然存在型マイクロ−ｒｎａ
US20120219958A1 (en) 2009-11-09 2012-08-30 Yale University MicroRNA Signatures Differentiating Uterine and Ovarian Papillary Serous Tumors
WO2014012081A2 (en) 2012-07-13 2014-01-16 Ontorii, Inc. Chiral control

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3647799A (en) * 1998-04-03 1999-10-25 Salk Institute For Biological Studies, The Ribozyme-mediated control of gene expression
US8106180B2 (en) 2003-08-07 2012-01-31 Whitehead Institute For Biomedical Research Methods and products for expression of micro RNAs
US8354384B2 (en) * 2005-06-23 2013-01-15 Yale University Anti-aging micrornas
DE102005059315A1 (de) * 2005-12-09 2007-06-14 Qiagen Gmbh Verfahren zur Anreicherung von kurzkettigen Nukleinsäuren
US20100144831A1 (en) * 2006-09-27 2010-06-10 Habib Fakhral Blocking of gene expression in eukaryotic cells
US20090004668A1 (en) 2007-06-22 2009-01-01 The Board Of Trustees Of The Leland Stanford Junior University Pre-miRNA loop-modulated target regulation
US8961961B2 (en) 2010-05-03 2015-02-24 a Tyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of arginyl-tRNA synthetases
WO2012078637A2 (en) 2010-12-06 2012-06-14 Immune Disease Institute, Inc. Composition and method for oligonucleotide delivery
WO2013106766A2 (en) 2012-01-13 2013-07-18 The Research Foundation Of State University Of New York THERAPEUTIC INDICATIONS OF miR-1291
WO2013170365A1 (en) * 2012-05-18 2013-11-21 The University Of British Columbia Compositions of sparc polypeptide and grp78, and methods and uses thereof for sensitizing cancer cells
JP2017506893A (ja) * 2014-02-18 2017-03-16 デューク ユニバーシティ ウイルス複製不活化組成物並びにその製造方法及び使用
EP3160980B1 (en) * 2014-05-28 2020-05-20 The Regents of the University of California HYBRID tRNA/pre-miRNA MOLECULES AND METHODS OF USE
WO2016153880A2 (en) 2015-03-23 2016-09-29 The Regents Of The University Of California Methods for detection of rnase activity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090298920A1 (en) 2006-06-14 2009-12-03 Universite Rene Descartes - Paris V Chimeric transfer rna and use thereof for the production of rna by a cell
JP2010527616A (ja) 2007-05-23 2010-08-19 ダーマコン， インコーポレイテッド マイクロ−ｒｎａスキャホールドおよび非天然存在型マイクロ−ｒｎａ
US20120219958A1 (en) 2009-11-09 2012-08-30 Yale University MicroRNA Signatures Differentiating Uterine and Ovarian Papillary Serous Tumors
WO2014012081A2 (en) 2012-07-13 2014-01-16 Ontorii, Inc. Chiral control

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ｍｏｌｅｃｕｌａｒ Ｃｅｌｌ， ２０１０， Ｖｏｌ．３７， ｐ．１３５－１４２

Also Published As

Publication number Publication date
EP3160980A1 (en) 2017-05-03
US10619156B2 (en) 2020-04-14
EP3160980B1 (en) 2020-05-20
JP2021003105A (ja) 2021-01-14
EP3160980A4 (en) 2018-03-21
JP2017524341A (ja) 2017-08-31
US20180237772A1 (en) 2018-08-23
WO2015183667A1 (en) 2015-12-03

Similar Documents

Publication Publication Date Title
JP7026440B2 (ja) ハイブリッドｔＲＮＡ／プレｍｉＲＮＡ分子および使用方法
Abd-Aziz et al. Development of microRNAs as potential therapeutics against cancer
Ibrahim et al. MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma
US11946049B2 (en) tRNA/pre-miRNA compositions and use in treating cancer
JP7011389B2 (ja) オリゴヌクレオチドの全身性イン－ビボ送達
WO2018039119A1 (en) Methods of suppressing delivery of exosomes to liver and spleen
Alexandri et al. The role of microRNAs in ovarian function and the transition toward novel therapeutic strategies in fertility preservation: from bench to future clinical application
US9642872B2 (en) Treatment of B-cell lymphoma with microRNA
Wu et al. MiRNAs in human cancers: the diagnostic and therapeutic implications
Dai et al. Pancreatic cancer: Nucleic acid drug discovery and targeted therapy
CN105765069A (zh) 肝癌相关的基因特异性siRNA、包含所述siRNA的双链寡RNA分子和包含它们的用于预防或治疗癌症的组合物
Kwak et al. A T7 autogene-based hybrid mRNA/DNA system for long-term shRNA expression in cytoplasm without inefficient nuclear entry
WO2023086935A2 (en) Aptamer-based small ribonucleic acid delivery platform and uses thereof
US12516329B2 (en) Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell
Bouillon et al. RNA-based precision medicine in glioblastoma driven by oncogenic gene fusions
Ho Bioengineering ncRNAs for Biomedical Research and Therapy
Myoung Development of an RNA-based Cancer Therapeutic Restoring Tumor Suppressor microRNA
da Costa MicroRnas as Molecular Targets for Non-Viral Gene Therapy of Glioblastoma: Development of a Lipid-Based Nanosystem for Nucleic Acid Delivery to Brain Tumor Cells
Li RNAi applications: development of approaches for selection of siRNAs and characterization of miRNA function in cancer
TW201717969A (zh) 用於治療與ｋｒａｓ突變相關之惡性腫瘤的方法與組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180516

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180516

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190329

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190411

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191010

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200715

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200715

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200722

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20200727

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20200918

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20200924

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210118

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210415

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210719

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20210916

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20211111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211215

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20211223

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20220120

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20220120

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220215

R150 Certificate of patent or registration of utility model

Ref document number: 7026440

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250